Pharmaco - Articles

This Conference will provide a platform for intellectual discourse in order to answer these questions and to discuss other pressing issues regarding the pharmaceutical industry in China in particular, and the world in general. Opportunities and challenges within the whole value chain, from research and development down to sales and marketing will be discussed and solutions put forward for the benefits of attendees.
WHAT YOU WILL TAKE AWAY FROM THIS CONFERENCE We believe that the quality of a conference program comes from listening to the requests and advice given by our target market. We pride ourselves in providing the most-up-to date subject matter suggested by the market in an environment that is conducive to networking and learning. At this event, you will have the unique opportunity…

In recent years, parallel trade of pharmaceutical products has grown to some the highest levels ever seen, exerting additional pressure on pharmaceutical companies' profitability. Companies need to be proactive to restrict parallel trade, especially in the EU, which is expected to continue to be the market of most concern for pharmaceutical firms.
Parallel trade of pharmaceutical products has risen over the past few years, driven by payers seeking to lower prescription drug expenditures and parallel traders seeking to cash in on the price differential of drugs in different countries. This has made parallel trade a growing concern for pharmaceutical companies - particularly those companies operating in the EU, where a high level of parallel trade exists because of EU law supporting the free…

Travellers’ Diarrhoea (TD) frequently occurs in individuals from industrialised countries when visiting destinations in developing countries. Consequences of TD include disruption of holiday and work capacity, and occasionally severe chronic disease. Existing methods of prevention are inadequate. We calculate that the number of travellers to TD risk regions was 88 million in 2003 and may reach 190 million per annum by 2020, suggesting that a significant potential market exists for a TD vaccine.
Travellers’ Diarrhoea – running amuck Travellers’ Diarrhoea (TD) is usually defined as the passage of at least three unformed stools in 24 hours, together with one or more symptoms such as fever, vomiting, or abdominal pain [1; 2].  It may arise as a result of infection by any of more than 20…

The Definitive Conference for Clinical Research Contract Professionals!
The Definitive Conference for Clinical Research Contract Professionals!FEATURING:New Format: 20 Sessions in 2 Tracks and 6 WorkshopsNew Session: Working with the Department of Veterans Affairs’ New CRADAs New Workshop: Sponsor/CRO Contracts and Relationships PHARMA PRESENTERS FROM:AllerganAstraZenecaBiogen IdecEli Lilly & CompanyNovartisPfizer

Off-label anti-coagulants, diuretics, and calcium-channel blockers are often used to treat pulmonary arterial hypertension (PAH), with more targeted therapies like endothelin receptor antagonists, phosphodiesterase-5 inhibitors and prostacyclins also used extensively. While these treatments have all shown considerable efficacy, their shortcomings leave considerable unmet need in the PAH market.
No consensus currently exists as to the actual prevalence of PAH. Most physicians and sources agree that the PAH population falls between 40,000 and 100,000 people, with companies interested in the PAH market citing US prevalence rates of 50,000. However, according to a new report, there are approximately 146,000 people suffering from PAH across the seven major markets, with the majority of these pat…

COPD is a disease that will grow in importance in the future and it will have a major impact on society, particular amongst those that smoke. At the moment, although new treatments are being developed for COPD the pharmaceutical market remains undeveloped. There will be a high demand for effective medicines and so COPD should be an area of interest for pharmaceutical companies who specialise in the respiratory therapeutic field.
A disease on the rise Respiratory diseases impose a tremendous health burden on society. According to the World Health Organization (WHO), in 2000, the top five respiratory accounted for 17.4% of all deaths worldwide (1). Worryingly, death and disability due to chronic obstructive pulmonary disorder (COPD) was identified as being on the increase (1).   WHO defi…

Healthcare is receiving greater attention in Latin America than ever before and a number of countries in the region are in the midst of major reforms. The government policies that are being developed have important implications for pharmaceutical companies looking to expand in this emerging pharmaceutical region.
Healthcare challenges Healthcare is receiving greater attention in Latin America than ever before and a number of countries in the region are in the midst of major reforms. However, these healthcare changes are taking place in an environment that is very different to many of the industrialised countries of the world, and are complicated by the profound social inequalities to be found across the region.   The provision of healthcare is an expensive task and requires ongoing in…

After the first failure of gene therapy, it's widely accepted that treatment leading to a cure for the 50,000 cystic fibrosis sufferers worldwide is an unachievable goal. The limited R&D efforts are instead directed towards disease modification and symptomatic treatments with ion channel modulators thought to hold some promise for the future.
Cystic fibrosis is an inherited disease that is caused by a mutation in the Cystic Fibrosis Transmembrane Conductance regulator (CFTR) gene. Although the most common mutation occurs at position 508 in the CFTR gene, advances in genomics have led to the discovery of a further 1,200 mutations. The CFTR mutation causes the chloride channel - which secretes chloride and water - to be blocked, which results in the production of thick mucus. The different mu…

If you attend only one Drug Discovery World Congress this year, you don't want to miss this event!
Access to Seven Concurrent Conferences1. Cell-Based Assays for HTS2. Cheminformatics3. Disease Models for Drug Discovery4. Driving DMPK5. Hit to Lead Optimization6. Strategies for Pharmaceutical Bioprocessing7. The Impact of Preclinical Drug Safety on R&D Productivity * Interactive Buzz Sessions and Panel Discussions* Sessions, Exhibit Hall, and Networking - All in One Convenient Location* In-Depth Short Courses* Enhanced Intro-Net Networking ToolCell-Based Assays for HTS

SMi’s Clinical Trials in Cancer conference will provide up-to-date information on the current challenges in clinical development, with an insight into European and US regulatory requirements. Attendees will benefit from presentations on key novel therapies currently in development and how they are being integrated into clinical trials. Don't miss this opportunity to meet experts in the field as they discuss how anti-cancer drug development can be optimised and carried forward to achieve the u
SMi’s Clinical Trials in Cancer conference will provide up-to-date information on the current challenges in clinical development, with an insight into European and US regulatory requirements. Attendees will benefit from presentations on key novel therapies currently in development and how they are…

I recently ran a quick poll on PharmiWeb, to determine what level of awareness there was for RSS (really simple syndication). So...
According to our quick RSS survey, 68% of respondents had no idea what it was or how to use it. This is a shame as we, and many other sites in the pharmaceutical industry are  providing them.So lets start with "what is RSS?" - essentially its a data standard that allows data to be made available in a format that can be easily picked up by a simple reader you install on your computer. In reality there are several standards, but most reader software reads them all. What this means to you is that by installing a small piece of software, you can elect to collect news (or whatever information sites make available) from across the web, and collect them into a si…

Corning Life Sciences today announced the addition of digital displays and enhanced features to its hot plates, stirrers and stirring hot plates. The new digital display features include: a digital temperature display adjustable in 5 degree increments and set temperature indicator; optimum digital stir speed display indicator; and an external temperature controller for precision accuracy “inside the beaker.”
FOR IMMEDIATE RELEASE — Media Relations Contact: Pamela D'Arcangelo(978) DArcangePJ@corning.com Corning Life Sciences Announces New Innovations for Existing Series of Hot Plates, Stirrers, and Stirring Hot Plates State-of-the-Art Digital Displays Provide Customers with Improved Safety Features and Advanced Ease-of-Use Capabilities ACTON, M.A., — Corning Incorporated (NYSE: ), a…

Corning Life Sciences today announced several new products coated with the Ultra-Low Attachment surface including the 25 and 75 cm2 flasks and CELLSTACK® Culture Chambers which are well-suited for many cell culture applications including stem cell, cancer, and immune system research, and enable customers to increase the scale of cell culture, improve yields, and reduce contamination risks
FOR IMMEDIATE RELEASE — Media Relations Contact: Pamela D'Arcangelo(978) DArcangePJ@corning.com Corning Life Sciences Announces New Ultra-Low Attachment Surface Products Offerings Enable Customers to Increase Scale and Improve Cell Yields for a Broad Range of New Applications ACTON, M.A., — Corning Incorporated (NYSE: ), a global supplier of scientific laboratory and drug discovery products for more…

Why ? Decision makers were not aware of the ROI that can have a search engine marketing strategy.
Over the last 8 years, Pharmaceutical companies and groups did not consider any move that attracts and recruit leads in the best cost effective way. Why ? Decision makers were not aware of the ROI that can have a search engine marketing strategy. elias KAI www.Google-kai.com

The antidyslipidemics market is driven by the statins, which account for 87% of this segment. However, as many statins are expected to face patent expiry in the coming decade manufacturers are looking to novel products to protect their franchise. Such products include combination such as Pfizer's atorvastatin/torcetrapib. Studies demonstrating that higher doses of existing products can offer improved efficacy but with no increase in side-effects will also help optimize sales in the antidyslipid
The antidyslipidemics market is driven by the statins, which account for 87% of this segment. However, as many statins are expected to face patent expiry in the coming decade manufacturers are looking to novel products to protect their franchise. Such products include combination such as Pfizer's at…

Heart failure affects more than 5 million people in the U.S. Approximately 20% of hospitalizations are due to acute congestive heart failure translating into a health-care system cost of $15 billion. Given the paucity of the pipeline for acute congestive heart failure, the best hope of clinical improvement will involve improved utilization of existing therapies. However early intervention requires rapid and accurate diagnosis. Given its diagnostic potential, the measurement of plasma BNP a
Heart failure affects more than 5 million people in the , and 550,000 new cases are diagnosed each year. It is the most common cause of hospitalization in people older than 65 years of age. Approximately 20% of hospitalizations are due to acute congestive heart failure translating into a health-care…

The 2nd international exhibition and conference event focussed exclusively on the theme of outsourcing in the research and development of new medicines. Companies both large and small are adopting this increasingly popular business strategy.
The 2nd international exhibition and conference event focussed exclusively on the theme of outsourcing in the research and development of new medicines. Companies both large and small are adopting this increasingly popular business strategy.  Pabord is relevant to service providers and R&D organisations active across the entire discovery and development chain from lead generation to product registration

e-Clinical Trials continue to be used more and more by the market leaders - There is no doubt though that the industry is soon to go fully electronic, so don't get behind the game... Our delegates have been demanding we run this event for the last 6 years! Here is what they have said about our past events: "...one of the best. I have learned a great deal about many of the important issues associated with e-Clinical Trials", Clinical Trial Manager/EDC Liason, Forest Labs Inc. "Informatio
6th Annual e-Clinical Trials conference 23 - 24 May 2006, London, UK Register your interest at www.clinicaltrialsevents.com Streamlining electronic systems to improve data management for clinical trials The industries leading e-Clinical Trials Conference is back - for the sixth year running! Whether…

Recent high-profile drug withdrawals have resulted in a new code of conduct to govern direct-to-consumer advertising. As more and more drugs are likely to come under regulatory and public scrutiny, the pharmaceutical industry will need to employ effective marketing and education strategies to ensure patient and physician confidence is retained and the impact of drug safety scares is minimized.
Concerns over drug safety and products being withdrawn due to adverse events or risks of serious side effects are not just a recent phenomenon. In fact, they can be traced back as far as the early 20th century, when the use of pharmaceuticals to cure and relieve disease began to gain momentum. Over 30 drugs have been withdrawn from the market in the last 20 years, with many more receiving 'black bo…

According to our recent feature Pain Therapeutics 2005 the value of the pharmaceutical market for pain relief approached $23 billion in 2004.  The pain market can be divided into acute pain which is well served by OTC medications, post-operative pain and chronic pain. One of the most challenging areas of analgesia is the treatment of chronic neuropathic pain.  Cancer pain also represents a largely unmet market which along with post-operative analgesia depends to a large extent on opioid-based th
According to our recent feature Pain Therapeutics 2005 the value of the pharmaceutical market for pain relief approached $23 billion in 2004.  The dynamics of the pain market have however altered greatly over the past few years, in particular as a result of the troubles surrounding the multi-bi…